We would welcome your comments on the draft paper entitled “All Wales Paediatric Asthma Management and Prescribing Guidelines”, the accompanying supporting notes “Paediatric Asthma Guideline supporting notes” and the associated Equality and Health Impact Assessment Form (EqHIA).
The All Wales Paediatric Asthma Management and Prescribing Guidelines have been developed as part of an integrated approach to standardise care across Wales for children with respiratory disease. This has been achieved through collaboration between the Welsh Paediatric Respiratory Network, with representatives from all hospitals in Wales and the Respiratory Health Implementation Group (RHIG).
Paediatric asthma is different to adult asthma in aetiology and in differential diagnosis. Different ages require different treatment considerations. This document sets out the patient pathway for Wales, explicit in management options for each healthcare setting, referral thresholds, and national medication choices. It is a document aimed at supporting a national, standardised, safer and sustainable approach to asthma care in children.
The document is based on recommendations from the British Thoracic Society and Scottish Intercollegiate British Guideline on the management of asthma (2019), NICE Guideline NG802, and the Global Initiative for Asthma (GINA): Asthma management and prevention guidelines (2022).
This consultation only considers the guideline content, and not the mobile technology application (app) or digital education platform referred to within the document, as these fall outside the remit of the All Wales Medicines Strategy Group (AWMSG).
Please access the document below, add any comments to our consultation pro‑forma and send it to us at: firstname.lastname@example.org
Closing date: Friday 10 February 2023